TGFβ pathways have been reported to play profound roles in cancer and cardiovascular diseases; in both situations, the anti-angiogenic effect of the downstream target TSP-1 can be harnessed therapeutically [33–35]. This evidence concerns the gene THBS1 and cardiovascular disorder.